Every weekday, CNBC Investing Club with Jim Cramer publishes the Homestretch — an actionable afternoon update, just in time for the ultimate hour of trading on Wall Street. Markets Rally: Stocks rose across the board Tuesday afternoon, led by the Nasdaq Composite, which rose 0.7% and was on course for 2 straight record closes. The S&P 500, which was near the zero line earlier within the session, rose about 0.4%. The Dow Jones Industrial Average pared earlier losses and gained about 100 points, or 0.25%. Great news for Lilly: The Food and Drug Administration approved Eli Lilly's Alzheimer's drug donanemab on Tuesday. The drug is sold under the brand name Kisunla and costs $32,000 for a 12-month course. On the news, Eli Lilly shares got here off session lows. The stock was under more pressure earlier within the day as President Joe Biden and Vermont Sen. Bernie Sanders criticized the price of the corporate's fast-growing weight-loss drug Zepbound. Kisunla will not be expected to be a big growth driver for Eli Lilly this 12 months or through 2025, especially considering the billions in projected sales for Zepbound and its sister drug Mounjaro, which has the identical energetic ingredient, tirzepatide, and is used to treat type 2 diabetes. Still, we view FDA approval of Lilly's Alzheimer's drug as a key catalyst for the corporate to achieve a $1 trillion market value. According to FactSet, analysts forecast Kisunla sales of $477 million in 2025 and around $1 billion in 2026. And Lilly is already working on next-generation treatments to follow on from Kisunla. Lilly had hoped to approve Kisunla by the top of March, however the timeline was pushed back after the FDA unexpectedly convened an advisory panel to take a more in-depth take a look at safety and effectiveness data. The 11-member panel finally met in June and voted unanimously in favor of the drug. Tuesday's approval represents a big breakthrough in Eli Lilly's decades-long, costly quest to seek out a treatment for Alzheimer's, a memory-robbing disease that afflicts hundreds of thousands of Americans. Before Kisunla, Lilly had been unsuccessful with several other experimental drugs, most notably solanezumab, which failed a high-profile late-stage trial in 2016. The company officially halted development of that drug last 12 months. Lilly's Kisunla is the second treatment of its kind to receive full FDA approval, following Leqembi, co-developed by Biogen and Eiasi, in July 2023. The drugs similarly aim to slow disease progression by reducing the formation of so-called amyloid plaques in a patient's brain. These abnormal clumps of the amyloid protein have long been an indicator of Alzheimer's disease, though their exact role within the disease is unknown. Both drugs are given intravenously. Leqembi's rollout has been slower than expected because the U.S. health care system worked to construct the infrastructure to support this latest class of treatment. Patients must first see a physician who can determine in the event that they are a candidate for the anti-amyloid drug. Then, intravenous infusions to manage the drug should be scheduled every two weeks, together with regular MRI scans to observe unintended effects, which include brain swelling and bleeding. Leqembi is dear, at greater than $26,000 a 12 months, so securing insurance reimbursement is one other key piece of the treatment puzzle. Biogen said in late April that Leqembi adoption is growing, and executives offered encouraging comments that hospital systems are higher prepared to treat patients with the drug. Lillly's entry into the Alzheimer's market could further speed up that progress, said Alisha Alaimo, head of Biogen's North American business. “In an area like this, where the medical community has done so much, having a competitor or another option is always a good thing,” Alaimo said at a Goldman Sachs healthcare conference on June 12. “That's a good thing for doctors. That's a good thing for patients. But more importantly, with Lilly in the game, the market will move faster.” We had already considered taking profits on Eli Lilly on Tuesday, but ultimately decided against it, since increased political risk from Washington within the short term does nothing to alter the pharmaceutical giant's long-term trajectory. We've been saying for years that its growth prospects are the very best amongst large-cap peers, with Mounjaro and Zepbound as anchors, and now Kisunla can officially be considered a part of history. Corona on the schedule: Club holding Constellation Brands is anticipated to report its quarterly results on Wednesday before the market opens. The post-earnings conference call is about for 10:30 a.m. ET. Although there have been some concerns that bad weather around Memorial Day could affect Constellation's quarter, several analysts remain bullish on the stock ahead of the earnings release. In a note to clients on Friday, Goldman Sachs said investor expectations were low attributable to weaker trends across the industry. But analysts said the parent company of Corona and Modelo is poised for a lift in sales and earnings based on feedback from its sales and retail contacts. According to LSEG estimates, Wall Street expects the corporate to earn $3.46 per share on revenue of $2.67 billion. We'll even be in search of commentary on how summer is shaping up for major Mexican beer brands and whether there's a rebound in Constellation's flagging wine and spirits business. Up next: The U.S. stock market closes early at 1 p.m. ET on Wednesday ahead of the Fourth of July holiday. It's closed Thursday for the vacation. Before the break, though, we'll take a take a look at June private wage growth via ADP's employment survey on Wednesday morning, in addition to weekly initial jobless claims. (A full list of stocks in Jim Cramer's Charitable Trust could be found here.) As a subscriber to CNBC Investing Club with Jim Cramer, you'll receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his Charitable Trust's portfolio. When Jim has discussed a stock on CNBC, he waits 72 hours after the trade alert is issued before executing the trade. THE INFORMATION REGARDING INVESTING CLUB SET FORTH ABOVE IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY AND OUR DISCLAIMER. NO FIDUCIARY OBLIGATION OR OBLIGATION IS PROVIDED BY OR CREATED BY RECEIVING INFORMATION RELATED TO INVESTING CLUB. NO PARTICULAR RESULT OR PROFIT IS GUARANTEED.
image credit : www.cnbc.com